Breakthrough in Cardiac Care Personalized Vitamin D3 Treatment Halves Recurrent Heart Attack Risk

A groundbreaking study conducted by heart researchers at Intermountain Health has revealed that a personalized, “target to treat” approach to Vitamin D3 supplementation can significantly reduce the risk of a second heart attack in patients who have previously suffered a myocardial infarction.

The pivotal findings from the large, randomized clinical trial, known as the TARGET-D trial, were presented at the 2025 American Heart Association Scientific Sessions in New Orleans.

The Targeted Approach: Key to Success

The study directly addressed the limitations of previous clinical trials, which had failed to link standard Vitamin D supplementation doses (typically $600$ to $800$ IU) to improved cardiovascular outcomes. Intermountain researchers hypothesized that achieving and maintaining an optimal blood level was the critical factor.

Dr. Heidi May, cardiovascular epidemiologist at Intermountain Health and the principal investigator, noted: “With more targeted treatment, when we checked exactly how supplementation was working and made adjustments, we found that patients had their risk of another heart attack cut in half.”

Study Methodology and Results

The TARGET-D trial enrolled 630 Intermountain Health patients who had experienced a heart attack within a month of enrollment, with follow-up extending until March 2025.

Treatment Goal: Patients in the active treatment arm were managed to raise their blood levels of Vitamin D to more than $40$ nanograms per ml (ng/mL).
High Deficiency Rate: A staggering 85% of the enrolled heart attack patients were found to have insufficient Vitamin D3 levels (less than $40$ ng/mL).
Dosage Requirement: To reach the target level, over 50% of the targeted treatment group initially required a high dose of $5,000$ international units (IU) of Vitamin D3.
Monitoring Protocol: Treated patients had their Vitamin D levels checked annually. If levels dropped below $40$ ng/mL, they were tested every three months, and dosages were adjusted until the optimal level was reached.
Outcome: While researchers found no significant difference in the overall risk of Major Adverse Cardiac Events (MACE—including heart attack, heart failure hospitalization, stroke, or death) between the groups, the risk of a follow-up heart attack specifically was reduced by 50% in the targeted management group.

Safety and Future Directions

Dr. May confirmed the safety profile of the targeted therapy, stating, “We observed no adverse outcomes when giving patients higher doses of vitamin D3 supplementation.”

The researchers stressed the urgency of these findings, given that one-half to two-thirds of people worldwide have low levels of Vitamin D. The next critical step is to conduct a larger-scale clinical trial to independently reaffirm the findings and more definitively evaluate the targeted strategy’s impact on other cardiovascular diseases.